{"name":"Biocad","slug":"biocad","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":17,"colorKey":"cardiovascular","drugs":[{"name":"BCD-148","genericName":"BCD-148","slug":"bcd-148","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"BCD-178","genericName":"BCD-178","slug":"bcd-178","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"BCD-217","genericName":"BCD-217","slug":"bcd-217","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"BCD-236","genericName":"BCD-236","slug":"bcd-236","indication":"Metastatic non-small cell lung cancer","status":"phase_2"},{"name":"Methotrexat","genericName":"Methotrexat","slug":"methotrexat","indication":"Acute lymphoid leukemia","status":"marketed"},{"name":"BCD-055","genericName":"BCD-055","slug":"bcd-055","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"BCD-057","genericName":"BCD-057","slug":"bcd-057","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"BCD-085 Q2W","genericName":"BCD-085 Q2W","slug":"bcd-085-q2w","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"BCD-085 Q4W","genericName":"BCD-085 Q4W","slug":"bcd-085-q4w","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"BCD-089","genericName":"BCD-089","slug":"bcd-089","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"BCD-100","genericName":"BCD-100","slug":"bcd-100","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"BCD-132","genericName":"BCD-132","slug":"bcd-132","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"BCD-201","genericName":"BCD-201","slug":"bcd-201","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"BCD-264","genericName":"BCD-264","slug":"bcd-264","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"BCD-281","genericName":"BCD-281","slug":"bcd-281","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"Cisplatin (or Carboplatin)","genericName":"Cisplatin (or Carboplatin)","slug":"cisplatin-or-carboplatin","indication":"Metastatic testicular cancer","status":"phase_3"},{"name":"anti-TRBV9 monoclonal antibody infusions","genericName":"anti-TRBV9 monoclonal antibody infusions","slug":"anti-trbv9-monoclonal-antibody-infusions","indication":"T-cell lymphomas expressing TRBV9","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"immunology","drugs":[{"name":"BCD-066","genericName":"BCD-066","slug":"bcd-066","indication":"Other","status":"phase_1"},{"name":"BCD-131","genericName":"BCD-131","slug":"bcd-131","indication":"Other","status":"phase_2"},{"name":"BCD-248","genericName":"BCD-248","slug":"bcd-248","indication":"Other","status":"phase_2"},{"name":"Acellbia","genericName":"Acellbia","slug":"acellbia","indication":"Other","status":"phase_3"},{"name":"Algeron","genericName":"Algeron","slug":"algeron","indication":"Other","status":"phase_3"},{"name":"empegfilrastim","genericName":"empegfilrastim","slug":"empegfilrastim","indication":"Other","status":"phase_2"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"BCD-063","genericName":"BCD-063","slug":"bcd-063","indication":"Psoriasis","status":"phase_3"},{"name":"Adalimumab subcutaneous injection","genericName":"Adalimumab subcutaneous injection","slug":"adalimumab-subcutaneous-injection","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"BCD-263","genericName":"BCD-263","slug":"bcd-263","indication":"Psoriasis (plaque psoriasis)","status":"phase_3"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"BCD-131 (pegdarbepoetin beta)","genericName":"BCD-131 (pegdarbepoetin beta)","slug":"bcd-131-pegdarbepoetin-beta","indication":"Anemia associated with chronic kidney disease","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"Copaxone-Teva","genericName":"Copaxone-Teva","slug":"copaxone-teva","indication":"Relapsing-remitting multiple sclerosis (RRMS)","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"respiratory","drugs":[{"name":"Sodium Enoxaparine","genericName":"Sodium Enoxaparine","slug":"sodium-enoxaparine","indication":"Prophylaxis of venous thromboembolism in surgical patients","status":"marketed"}]}],"pipeline":[{"name":"BCD-063","genericName":"BCD-063","slug":"bcd-063","phase":"phase_3","mechanism":"BCD-063 is a monoclonal antibody that binds to and inhibits IL-17A, a pro-inflammatory cytokine involved in autoimmune and inflammatory diseases.","indications":["Psoriasis","Psoriatic arthritis"],"catalyst":""},{"name":"BCD-066","genericName":"BCD-066","slug":"bcd-066","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"BCD-131","genericName":"BCD-131","slug":"bcd-131","phase":"phase_2","mechanism":"BCD-131 is a small molecule that targets the [insert target here, if known].","indications":[],"catalyst":""},{"name":"BCD-148","genericName":"BCD-148","slug":"bcd-148","phase":"phase_3","mechanism":"BCD-148 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation)"],"catalyst":""},{"name":"BCD-178","genericName":"BCD-178","slug":"bcd-178","phase":"phase_3","mechanism":"BCD-178 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation)"],"catalyst":""},{"name":"BCD-217","genericName":"BCD-217","slug":"bcd-217","phase":"phase_3","mechanism":"BCD-217 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation)"],"catalyst":""},{"name":"BCD-236","genericName":"BCD-236","slug":"bcd-236","phase":"phase_2","mechanism":"BCD-236 is a small molecule that targets the PI3K/AKT pathway.","indications":["Metastatic non-small cell lung cancer","Metastatic breast cancer"],"catalyst":""},{"name":"BCD-248","genericName":"BCD-248","slug":"bcd-248","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Methotrexat","genericName":"Methotrexat","slug":"methotrexat","phase":"marketed","mechanism":"Canalicular multispecific organic anion transporter 1, High mobility group protein B1, Multidrug resistance-associated protein 4","indications":["Acute lymphoid leukemia","Burkitt's lymphoma","Carcinoma of female breast","Crohn's disease","Erythrodermic psoriasis"],"catalyst":""},{"name":"Acellbia","genericName":"Acellbia","slug":"acellbia","phase":"phase_3","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Adalimumab subcutaneous injection","genericName":"Adalimumab subcutaneous injection","slug":"adalimumab-subcutaneous-injection","phase":"phase_3","mechanism":"Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.","indications":["Rheumatoid arthritis","Inflammatory bowel disease (Crohn's disease and ulcerative colitis)","Psoriasis","Ankylosing spondylitis","Polyarticular juvenile idiopathic arthritis"],"catalyst":""},{"name":"Algeron","genericName":"Algeron","slug":"algeron","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BCD-055","genericName":"BCD-055","slug":"bcd-055","phase":"phase_3","mechanism":"BCD-055 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation)"],"catalyst":""},{"name":"BCD-057","genericName":"BCD-057","slug":"bcd-057","phase":"phase_3","mechanism":"BCD-057 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation)"],"catalyst":""},{"name":"BCD-085 Q2W","genericName":"BCD-085 Q2W","slug":"bcd-085-q2w","phase":"phase_3","mechanism":"BCD-085 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation)"],"catalyst":""},{"name":"BCD-085 Q4W","genericName":"BCD-085 Q4W","slug":"bcd-085-q4w","phase":"phase_3","mechanism":"BCD-085 is a monoclonal antibody that blocks the PD-L1 checkpoint, enabling the immune system to recognize and attack cancer cells.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation in Phase 3)"],"catalyst":""},{"name":"BCD-089","genericName":"BCD-089","slug":"bcd-089","phase":"phase_3","mechanism":"BCD-089 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation)"],"catalyst":""},{"name":"BCD-100","genericName":"BCD-100","slug":"bcd-100","phase":"phase_3","mechanism":"BCD-100 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation)"],"catalyst":""},{"name":"BCD-131 (pegdarbepoetin beta)","genericName":"BCD-131 (pegdarbepoetin beta)","slug":"bcd-131-pegdarbepoetin-beta","phase":"phase_3","mechanism":"BCD-131 is a pegylated erythropoiesis-stimulating agent that binds to and activates the erythropoietin receptor to stimulate red blood cell production.","indications":["Anemia associated with chronic kidney disease","Chemotherapy-induced anemia"],"catalyst":""},{"name":"BCD-132","genericName":"BCD-132","slug":"bcd-132","phase":"phase_3","mechanism":"BCD-132 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation)"],"catalyst":""},{"name":"BCD-201","genericName":"BCD-201","slug":"bcd-201","phase":"phase_3","mechanism":"BCD-201 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation)"],"catalyst":""},{"name":"BCD-263","genericName":"BCD-263","slug":"bcd-263","phase":"phase_3","mechanism":"BCD-263 is a monoclonal antibody that binds to and inhibits IL-17A, a pro-inflammatory cytokine involved in autoimmune and inflammatory diseases.","indications":["Psoriasis (plaque psoriasis)","Rheumatoid arthritis","Ankylosing spondylitis"],"catalyst":""},{"name":"BCD-264","genericName":"BCD-264","slug":"bcd-264","phase":"phase_3","mechanism":"BCD-264 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation)"],"catalyst":""},{"name":"BCD-281","genericName":"BCD-281","slug":"bcd-281","phase":"phase_3","mechanism":"BCD-281 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation)"],"catalyst":""},{"name":"Cisplatin (or Carboplatin)","genericName":"Cisplatin (or Carboplatin)","slug":"cisplatin-or-carboplatin","phase":"phase_3","mechanism":"Cisplatin and carboplatin are platinum-based chemotherapy agents that bind to DNA and form cross-links, preventing DNA replication and transcription to kill rapidly dividing cancer cells.","indications":["Metastatic testicular cancer","Ovarian cancer","Non-small cell lung cancer","Head and neck cancer","Bladder cancer"],"catalyst":""},{"name":"Copaxone-Teva","genericName":"Copaxone-Teva","slug":"copaxone-teva","phase":"phase_3","mechanism":"Glatiramer acetate is a synthetic polypeptide that modulates immune responses by promoting anti-inflammatory T cell and B cell activity in multiple sclerosis.","indications":["Relapsing-remitting multiple sclerosis (RRMS)","Clinically isolated syndrome (CIS) with high risk of MS"],"catalyst":""},{"name":"Sodium Enoxaparine","genericName":"Sodium Enoxaparine","slug":"sodium-enoxaparine","phase":"marketed","mechanism":"Sodium enoxaparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa.","indications":["Prophylaxis of venous thromboembolism in surgical patients","Treatment of acute deep vein thrombosis","Treatment of acute pulmonary embolism","Prophylaxis in medically immobilized patients","Acute coronary syndrome (unstable angina and non-ST elevation myocardial infarction)"],"catalyst":""},{"name":"anti-TRBV9 monoclonal antibody infusions","genericName":"anti-TRBV9 monoclonal antibody infusions","slug":"anti-trbv9-monoclonal-antibody-infusions","phase":"phase_3","mechanism":"This monoclonal antibody targets and depletes T cells expressing the TRBV9 T-cell receptor beta variable segment, selectively eliminating a subset of pathogenic T cells in autoimmune and T-cell malignancy conditions.","indications":["T-cell lymphomas expressing TRBV9","Autoimmune diseases with TRBV9-positive T-cell involvement"],"catalyst":""},{"name":"empegfilrastim","genericName":"empegfilrastim","slug":"empegfilrastim","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNSGhYdHFUTGVnNlE3aDJqMGQtdGNZRmIxY0E0MFRJMHo1eExGUzR6R0ItOHp2M2tiYkQwRkZDLTFiUHRuRW5CeEtwaFNuTXBmeUJQMzJldEtqXzQxOWFkZXkyalBham5uTEE2aGk0SnhDd3BpR2N1c2IzM3Y1WmVGRHRaLTItSUtOSDZZadIBjAFBVV95cUxNSGhYdHFUTGVnNlE3aDJqMGQtdGNZRmIxY0E0MFRJMHo1eExGUzR6R0ItOHp2M2tiYkQwRkZDLTFiUHRuRW5CeEtwaFNuTXBmeUJQMzJldEtqXzQxOWFkZXkyalBham5uTEE2aGk0SnhDd3BpR2N1c2IzM3Y1WmVGRHRaLTItSUtOSDZZaQ?oc=5","date":"2025-06-10","type":"pipeline","source":"Новости GxP","summary":"The founder of Promomed has become a new billionaire - Новости GxP","headline":"The founder of Promomed has become a new billionaire - Новости GxP","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-04-18","type":"pipeline","source":"Qatar Tribune","summary":"QFZ Authority, BIOCAD sign MoU to boost biotech and pharma in Qatar - Qatar Tribune","headline":"QFZ Authority, BIOCAD sign MoU to boost biotech and pharma in Qatar","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPZ0Z3RjdpbjlPVWRERmpXYld3TG5rbGNVVjZVR2U2ZDZKNDdJTDZ4MElrUW1KX0czRTFnWVM3bWVSTGJoa2J2VG1lUEo4ZlltQ29QT1NtdWg2VC1FNUhFd2oxVjdVampYQjVCT0dTU3YwbFlqcFQ4eHI2ZjBrcFRSWDdtV3dfMk1nUGNxTms4cTFWRVJ6SDNHWEprVWtoLTU4eE5iU1cwVHJ4WW83aGcwY0dKM1BnUnZOY2dV?oc=5","date":"2022-08-11","type":"pipeline","source":"The Pharma Letter","summary":"Biocad sets sights on being leading supplier of cancer drugs in Russia - The Pharma Letter","headline":"Biocad sets sights on being leading supplier of cancer drugs in Russia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxPS0pYR1QwbFFCWHdPVHN1ZjI1Vzd0UzVwMVl4TEZscU4yN0hUY3NhS1dYVGQyd0c5YS1hQ0p1V0duc0dHZWE2Nm5WTUxmaVo0ZnFSMnFIX1BZX1VxV19EanhaN2F4RXlVdmZSbUR5NFM0Zkx0TjB3TWtMZnpMVWNHX21ZN1NpN0tLcEZWNEFGWEQ5YjNSbXc4MWlUa08wMDRZNW1KeVdFU0JGRDkzYmkyNVV3NV91MllTWnFfYi1WUGhVdEszZHI3ZHo2N1hqVFRrLUFHVQ?oc=5","date":"2021-07-02","type":"patent","source":"Generics and Biosimilars Initiative","summary":"Shanghai Pharma and Russia’s Biocad form joint venture to sell cancer and autoimmune drugs in China - Generics and Biosimilars Initiative","headline":"Shanghai Pharma and Russia’s Biocad form joint venture to sell cancer and autoimmune drugs in China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxONm5saVliUXc0SE41aGJxU0tXWFp3SXdJQms0TDFSVklqRFN0UFE4ei13OUFRQkpjNHhEdld5ckxVaFJKZDVkSDgxZkZmdndFMmFydWhDSW1VSktFbVNuTm9uSmpzdC1pR0hEWGVlMnBmOFQ0d2VlS0NWdWFfVlE0cXEzSi1uTzQwVzFZdnJB?oc=5","date":"2021-06-30","type":"patent","source":"Generics and Biosimilars Initiative","summary":"Biocad to be taken over by Russian investment firm - Generics and Biosimilars Initiative","headline":"Biocad to be taken over by Russian investment firm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxOZWtKRmM4OUs1MU9GM1Y1cGY1dnNJSG5BWUE2dTdoNEhFN3NUM1NKbDdFTGFoT0g5RkgtRHkxMi1Na3hQYU0wTjFQX1JnR3d4NGNBNUttU3ZXSUc3TWJVR1hENHJXcWlUd19rY0dQSWs4aHVfWWl3VS1LY2hYRGI3NTNOSUFVZy12dHBtOThXTHJVWkdxSzM1SnJJZEJlLUd3QmxmR1hUSEdPc0tjMUMxR0dxTTMtTUtRNHdsTjFGcTdOZHY1?oc=5","date":"2019-11-06","type":"patent","source":"Fierce Pharma","summary":"Roche escapes lawsuit claiming it illegally quashed Biocad's biosimilar hopes - Fierce Pharma","headline":"Roche escapes lawsuit claiming it illegally quashed Biocad's biosimilar hopes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQUVhqdTV3eEpEMXhZSGxCVXBwcXJKY3pJeS1jQWQ2al9pb1RVV0dzS2lzOUNnSVNsR0ZpNGVmVEFZaFoxb1EzTzdfUkg5bWd0dkNFR2lrZnVNWGZhTWxLRlRHd2UwN2FSdmtaLWFWTzVqNlFQVW9lc243dUFvWEVGWHJGdmFLMVVhWXFTQ1FDcUpPWlhRc1RRQjJ0cTVFVHl4VWgtWGprN0dtZTFGWUUzMzkzeGRKUHFO?oc=5","date":"2019-09-19","type":"pipeline","source":"Yicai Global","summary":"Shanghai Pharma, Russia's Biocad Plan JV to Sell Cancer, Autoimmune Drugs in China - Yicai Global","headline":"Shanghai Pharma, Russia's Biocad Plan JV to Sell Cancer, Autoimmune Drugs in China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNQjVraEx1WF9Dbm5YUDRmWGZOZTdyVnJ2dWZLYXlyN0VveHlaSmVRSXlMM29vZjlJU01FeWlUX1Q4SEZ4LWw2SnREOVVpeEttTnZCQWUtR256X2lSczYtZ3hSbXRZRUgtcWpXNkotVVEyeWFEaWFGVnhBY1dtR19BdEZXOXZFdndZcWQ3M1hSUEx4dGtLSExTTHlZd1hMQWZlZ3huTVFsQ0J5UDVrYmRPcy1SenY3ZzE1?oc=5","date":"2018-09-14","type":"pipeline","source":"BioSpectrum Asia","summary":"BIOCAD, SPH to build drug substance manufacturing facility in China - BioSpectrum Asia","headline":"BIOCAD, SPH to build drug substance manufacturing facility in China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQT2pHbER6NV81MFl5VmgyZlBGc0tkd1hLVEpwNzROS0RQWGFyVF9aeVNQYWpNakFqcTc0dU9DN21Pc3JYbUZTcWdLUVU0TEZwblRMMmFjVzB0ZWpNMmxTZ2lTZTh0SjJ4dE44N3RlMlVDOTZnMzkzZHVhZm5nWU9JZVFtQmd3cnZhRy0tekgxVVJCbjhIeHJKY1B0dw?oc=5","date":"2017-12-14","type":"patent","source":"BioPharma Dive","summary":"Biocad set to begin selling biosimilars in North Africa - BioPharma Dive","headline":"Biocad set to begin selling biosimilars in North Africa","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPRmx6VG8zejNyZXg4SWJKQmxpbzEwcmxPV3QwdGdzODhSYnV2bldRN1ZGQ01jclJQemVaTUdKckNPUnR6NjhVU2hjRTVGWHB1MlJfYTNwNTdvM19fSFAyQkFtWHBHRWIyMXpSOC1WTDdjTkx3emUyNTFiSEM3c2ZjbWtDdEY2Rk5uT21hLUREMVhMWkJ1OUZSS1BiM0owZXlhTXc?oc=5","date":"2017-12-01","type":"pipeline","source":"Contract Pharma","summary":"BIOCAD Launches New Mfg. Site in North Africa - Contract Pharma","headline":"BIOCAD Launches New Mfg. Site in North Africa","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxNdVA0d2hIdXlScjdwQVBxNWtta1Y4M0VmZjI1RTU4UXFnOW5EeGVkMnF1bklqVzlmcC1ZYnhqWnZUa1RwNFk2LXJ2SG5QeTRFS0YtQnNEMTR4bnJlbFJ4cEtVSHF0cnpqdDVlRGRGdFpkVUVVdjF2N3ZGSU9mV3YxbTVZME5pekw3eW5DVHdCd3JDUDIzUzcyV2tMZUJMX2c0SU5SVHhDSVA4VXAzTVlN?oc=5","date":"2017-11-29","type":"deal","source":"Fierce Pharma","summary":"Russian biotech Biocad inks deal to manufacture biosimilars in Morocco - Fierce Pharma","headline":"Russian biotech Biocad inks deal to manufacture biosimilars in Morocco","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPYy1fVDdCc0hSUzhudUFaalM5S3hUbFI5ekVETWs1ODh5OGxuNGZmZU83dGtmVUlaZ1NOQXBzZ1BGdUhOZTE0WGdFUThBeVNVVE5DU1dheVZoZVFKd3AwUENyQzdiV1ctZWpjdkhtVGozZ2ItYjA3bFZKX2t4UTZpVUhkblQtZE1XUTlpX0RSMHFBZUtMQ2JCbFpicDhIRi0zeG9fblgxT0tvSFMxMUJHbFptUkhsUQ?oc=5","date":"2017-10-26","type":"patent","source":"Center for Biosimilars","summary":"Biocad Wins Rituximab Patent Challenge, Plans to Enter the European Market - Center for Biosimilars","headline":"Biocad Wins Rituximab Patent Challenge, Plans to Enter the European Market","sentiment":"neutral"}],"patents":[],"drugCount":29,"phaseCounts":{"phase_3":22,"phase_1":1,"phase_2":4,"marketed":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}